Drugs / CCT303-406
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04511871 | Jul 2020 → Oct 2024 overdue | breast cancer, gastric cancer, ovarian cancer, sarcoma | Shanghai PerHum Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCT303-406 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04511871 ↗ |
| Modality | Cell therapy | “CCT303-406 CAR modified autologous T cells” NCT04511871 ↗ |
| Route | Intravenous | “via intravenous injection” NCT04511871 ↗ |